Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4
暂无分享,去创建一个
P. Nelson | Yuzhuo Wang | C. Morrissey | E. Corey | J. Alumkal | Xuesen Dong | Duanchen Sun | Zheng Xia | Ahn R Lee | Ilsa M. Coleman | Ilsa M Coleman | David A. Sampson | Jacob Schwartzman | Daniel J. Coleman | A. Kumaraswamy | A. Sehrawat | J. Yates | Joshua Urrutia | Ahn R. Lee
[1] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[2] P. Nelson,et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. , 2019, The Journal of clinical investigation.
[3] T. Graeber,et al. Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. , 2019, Cancer cell.
[4] Laura M. Heiser,et al. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer , 2019, Oncogene.
[5] Laura M. Heiser,et al. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer , 2019, Scientific Reports.
[6] James C. Hu,et al. The Gene Ontology Resource: 20 years and still GOing strong , 2019 .
[7] M. Gleave,et al. SRRM4 gene expression correlates with neuroendocrine prostate cancer , 2018, The Prostate.
[8] Yuxin Tang,et al. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network , 2018, EBioMedicine.
[9] Joshua M. Stuart,et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] William H. Bisson,et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function , 2018, Proceedings of the National Academy of Sciences.
[11] A. Zoubeidi,et al. Cellular plasticity and the neuroendocrine phenotype in prostate cancer , 2018, Nature Reviews Urology.
[12] K. Tanabe,et al. Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer , 2017, Annals of Surgical Oncology.
[13] Astrid Gall,et al. Ensembl 2018 , 2017, Nucleic Acids Res..
[14] C. Collins,et al. Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4 , 2017, Oncotarget.
[15] Qiuyue Wang,et al. TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer , 2017, Oncotarget.
[16] Qiuyue Wang,et al. TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer , 2017, Oncotarget.
[17] Wenlin Huang,et al. BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer , 2017, Cell Death & Disease.
[18] P. Nelson,et al. LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.
[19] Kenji Suzuki,et al. LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer , 2016, Biochemistry and biophysics reports.
[20] N. Landsberger,et al. LSD1 Neurospecific Alternative Splicing Controls Neuronal Excitability in Mouse Models of Epilepsy. , 2015, Cerebral cortex.
[21] P. Nelson,et al. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.
[22] M. Esteller,et al. Identification of HERC5 and its potential role in NSCLC progression , 2015, International journal of cancer.
[23] B. Garcia,et al. A specific LSD1/KDM1A isoform regulates neuronal differentiation through H3K9 demethylation. , 2015, Molecular cell.
[24] E. Ben-Jacob,et al. Prostate Cancer and Neuroendocrine Differentiation: More Neuronal, Less Endocrine? , 2015, Front. Oncol..
[25] R. Darnell,et al. Microexons—Tiny but mighty , 2015, The EMBO journal.
[26] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[27] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[28] Jernej Ule,et al. A global regulatory mechanism for activating an exon network required for neurogenesis. , 2014, Molecular cell.
[29] P. Nelson,et al. Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular “pseudoinflammation” contributing to an aggressive phenotype , 2014, Oncotarget.
[30] Shanhong Tang,et al. [Significance of SAMD9 expression in esophageal squamous cell carcinoma]. , 2014, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.
[31] M. Tortorici,et al. Phosphorylation of neuronal Lysine‐Specific Demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2 , 2014, Journal of neurochemistry.
[32] M. Rubin,et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.
[33] S. Ye,et al. BST-2 is a potential activator of invasion and migration in tamoxifen-resistant breast cancer cells. , 2013, Biochemical and biophysical research communications.
[34] Sean R. Davis,et al. NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..
[35] Bernd Fritzsch,et al. A Mutation in the Srrm4 Gene Causes Alternative Splicing Defects and Deafness in the Bronx Waltzer Mouse , 2012, PLoS genetics.
[36] Qun Pan,et al. Cross-regulation between an alternative splicing activator and a transcription repressor controls neurogenesis. , 2011, Molecular cell.
[37] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[38] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[39] J. C. Belmonte,et al. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells , 2011, Nature Cell Biology.
[40] Y. Kaneda,et al. Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ‐E) or type I interferon , 2010, International journal of cancer.
[41] F. Forneris,et al. Alternative Splicing of the Histone Demethylase LSD1/KDM1 Contributes to the Modulation of Neurite Morphogenesis in the Mammalian Nervous System , 2010, The Journal of Neuroscience.
[42] Jie Cao,et al. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis , 2009, BMC Cancer.
[43] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] Hubert Vesselle,et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. , 2003, Human pathology.
[45] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[46] C. Collins,et al. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. , 2017, European urology.
[47] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..